In this single-center study, 16 stable renal transplant recipients were observed for 1 year after a milligram to milligram switch from standard-release to prolonged-release tacrolimus formulation. Trough blood tacrolimus level and graft function were serially monitored.
Mean daily dose of tacrolimus was 0.040 ¡À 0.018 mg/kg before conversion. After conversion, we observed a significant decrease in trough tacrolimus levels, from 4.5 ¡À 2.2 ng/mL to 3.4 ¡À 1.1 ng/mL (p = 0.046) at 1 month, and from 4.5 ¡À 2.2 ng/mL to 3.3 ¡À 1.1 ng/mL (p = 0.01) at 12 months. After 12 months, 44 % of patients (n = 7) experienced a decrease in tacrolimus blood levels of more than 20 % . All patients maintained stable graft function otherwise, without acute rejection.
Our findings confirm that trough tacrolimus blood level can decrease following a 1:1 (mg:mg) conversion from standard-release to prolonged-release tacrolimus formulation in Chinese patients. Close monitoring of the drug levels and clinical condition seems to be warranted after medication switch.
ÄËÊá·ÅÐÍ tacrolimus ÞDQÖÁÒ»ÌìÒ»´ÎÑÓéLá·ÅÐÍ tacrolimus ͨ³£ÊÇ°´ 1:1 (mg:mg) µÄ±ÈÀýßMÐУ»ÒÔÏÂÑо¿ÒÔÈAÒáÄIÅKÒÆÖ²½ÓÊÜÕßé¦Ï󣬦´ËÞDQ·¨µÄ¹¦Ð§¼°°²È«ÐÔ×÷³öÕ{²é?h4 class=""h4"">·½·¨
±¾Ñо¿ì¶ÎÒ»ÔºËùßMÐУ¬ ¢ÅcÕßé 16 λ·¶¨µÄÄIÅKÒÆÖ²½ÓÊÜÕߣ¬ÄËÊá·ÅÐÍÞDQÖÁÑÓéLá·ÅÐÍ tacrolimus (?1:1 ?mg:mg ±ÈÀý) áá½Ó?1 ÄêµÄ³ÖÀm×·Û£¬ÈÈÝ°ü?tacrolimus ¹Èµ×ѪҺâ¶È¼°Ö²ÈëÄIÅK¹¦ÄÜ?h4 class=""h4"">½Y¹û
ÞDQÇ°£¬tacrolimus ֮ƽ¾ù©Á¿é 0.040 ¡À 0.018 mg/kg£»ÞDQáᣬtacrolimus ¹Èµ×â¶È³Ê¬FÃ÷ï@Ͻµ? ÔÂrÄ 4.5 ¡À 2.2 ng/mL ?3.4 ¡À 1.1 ng/mL (p = 0.046)?2 ÔÂrÄ 4.5 ¡À 2.2 ng/mL ?3.3 ¡À 1.1 ng/mL (p = 0.01)¡£ÔÚ½ß^ 12 ÔÂáᣬ44 % µÄ²¡?(n = 7) ³Ê¬F >20 % ?tacrolimus ѪҺâ¶È½µ·ù¡£È»¶ø£¬ËùÓв¡È˵ÄÖ²ÈëÄIÅK¾ù¾S³Ö·¶¨µÄ¹¦ÄÜ£¬Î´³ö¬F¼±ÐÔÅųâ¬FÏó?h4 class=""h4"">½YÕ
±¾Ñо¿×CÔÚÈAÒᲡÈËég£¬ÄËÊá·ÅÐÍ tacrolimus ?1:1 (mg:mg) ±ÈÀýÞDQÖÁÑÓéLá·ÅÐÍ tacrolimus áᣬtacrolimus ¹Èµ×â¶ÈþÓÐËùϽµ£¬Òò´ËÀíªÓÐÐèÒªÔÚÞDQááÃÜÇбO²ì²¡È˵ÄËÎïâ¶È¼°ÅR´² îr?/div>